Plasma fibrinogen, tissue plasminogen activator, plasminogen activator inhibitor 1, and their related factors in three Japanese population samples

[1]  M. Taskinen,et al.  The insulin resistance syndrome and postprandial lipid intolerance in smokers. , 1997, Atherosclerosis.

[2]  P C Elwood,et al.  Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. , 1996, European heart journal.

[3]  C. Jern,et al.  Enhanced levels of tissue-type plasminogen activator in borderline hypertension. , 1995, Hypertension.

[4]  M. Taskinen,et al.  The insulin resistance syndrome in smokers is related to smoking habits. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[5]  G. Mancia,et al.  Mechanisms Responsible for Sympathetic Activation by Cigarette Smoking in Humans , 1994, Circulation.

[6]  J. Seidell,et al.  Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. , 1994, Atherosclerosis.

[7]  A. Folsom,et al.  Antigens of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor 1: Correlates in Nonsmoking Japanese and Caucasian Men and Women , 1993, Thrombosis and Haemostasis.

[8]  A. Folsom,et al.  Plasma fibrinogen and its correlates in Japanese and US population samples. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[9]  P. Ridker,et al.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.

[10]  G. Reaven,et al.  Insulin resistance and cigarette smoking , 1992, The Lancet.

[11]  T. Urano,et al.  PAI-1 Plays an Important Role in the Expression of t-PA Activity in the Euglobulin Clot Lysis by Controlling the Concentration of Free t-PA , 1991, Thrombosis and Haemostasis.

[12]  A. Hamsten,et al.  Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. , 1990, Arteriosclerosis.

[13]  Aric Invest.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators , 1989 .

[14]  A. Folsom,et al.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. , 1989, American journal of epidemiology.

[15]  E. Kruithof,et al.  Diurnal Variation of the Fibrinolytic System , 1988, Thrombosis and Haemostasis.

[16]  T. Meade,et al.  EFFECTS OF CHANGES IN SMOKING AND OTHER CHARACTERISTICS ON CLOTTING FACTORS AND THE RISK OF ISCHAEMIC HEART DISEASE , 1987, The Lancet.

[17]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[18]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[19]  P. Vague,et al.  Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. , 1987, Diabete & metabolisme.

[20]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[21]  R D Moore,et al.  Moderate Alcohol Consumption and Coronary Artery Disease: A REVIEW , 1986, Medicine.

[22]  G. Wolfbauer,et al.  Studies on the binding and degradation of human very-low-density lipoproteins by human hepatoma cell line HepG2. , 1986, Biochimica et biophysica acta.

[23]  M. C. Stone,et al.  Plasma fibrinogen--a major coronary risk factor. , 1985, The Journal of the Royal College of General Practitioners.

[24]  L. Wilhelmsen,et al.  Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.

[25]  P. Wallén,et al.  An Enzyme Linked Immunosorbent Assay for Determination of Tissue Plasminogen Activator Applied to Patients with Thromboembolic Disease , 1983, Thrombosis and Haemostasis.

[26]  W. Kannel,et al.  Drinking habits and cardiovascular disease: the Framingham Study. , 1983, American heart journal.

[27]  H. Ueshima,et al.  [The evaluation and the results of cooperative cholesterol and triglyceride standardization program by WHO-CDC (author's transl)]. , 1982, Rinsho byori. The Japanese journal of clinical pathology.

[28]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[29]  A. C. Burton,et al.  RECOMMENDATIONS for human blood pressure determinations by sphygmomanometers. , 1967, Journal of the American Medical Association.

[30]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[31]  G. Assmann,et al.  Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[32]  L. Poller.  Recent Advances in Blood Coagulation , 1994 .

[33]  L. Mannucci,et al.  Hypertriglyceridemia and regulation of fibrinolytic activity. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[34]  G. Schaafsma,et al.  Regular moderate wine consumption for five weeks increases plasma activity of the plasminogen activator inhibitor-1 (PAI-1) in healthy young volunteers , 1990 .

[35]  V. Nguyen.  Fibrinogen and risk of cardiovascular disease: Kannel WB, Wolf PA, Castelli WP, et al JAMA 258: 1183–1186 Sep 1987 , 1988 .

[36]  A. Dyer,et al.  Alcohol consumption and 17-year mortality in the Chicago Western Electric Company study. , 1980, Preventive medicine.